' 
SCIENTIFIC SCORE
Likely Very Effective
Based on 2 Researches
9
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: About 1/4 cup (31 g)
Amount Per Serving
%DV
Calories
180
Total Fat
13 g
17%
Saturated Fat
3 g
15%
Trans Fat
0 g
Cholesterol
0 mg
0%
Sodium
0 mg
0%
Total Carbohydrate
4 g
1%
Dietary Fiber
2 g
7%
Total Sugars
0 g
Includes 0g Added Sugars
0%
Protein
11g
Vit. D
0 mcg
0%
Calcium
8 mg
0%
Iron
4 mg
20%
Potassium
243 mg
6%
Top Medical Research Studies
9
Potential migraine treatment revealed
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.
Highly relevant to migraine treatment
We explored the potential effectiveness of MEDI0618, a monoclonal antibody designed to target protease-activated receptor 2 (PAR2), in alleviating headache pain, particularly migraine. This study used various human and rodent models to evaluate how well MEDI0618 could prevent headache-like symptoms.
Our results showed that MEDI0618 uniquely binds to human PAR2 and effectively prevented pain signals in multiple migraine models. By administering MEDI0618 before triggering migraine-like pain with different methods, we found that it successfully reduced cutaneous allodynia—a condition where even light touch causes pain. This was particularly impressive since MEDI0618 worked even when CGRP receptor activity was blocked by another drug, establishing a broad effectiveness against migraine-related pain.
However, when we looked at a model of post-traumatic headache, MEDI0618 did not show benefits, suggesting it may not be effective for all types of headache pain. Overall, our findings indicate that MEDI0618 could offer a new route for migraine prevention, particularly for attacks that depend on pathways independent of CGRP, providing hope for many who suffer from migraines.
Our results showed that MEDI0618 uniquely binds to human PAR2 and effectively prevented pain signals in multiple migraine models. By administering MEDI0618 before triggering migraine-like pain with different methods, we found that it successfully reduced cutaneous allodynia—a condition where even light touch causes pain. This was particularly impressive since MEDI0618 worked even when CGRP receptor activity was blocked by another drug, establishing a broad effectiveness against migraine-related pain.
However, when we looked at a model of post-traumatic headache, MEDI0618 did not show benefits, suggesting it may not be effective for all types of headache pain. Overall, our findings indicate that MEDI0618 could offer a new route for migraine prevention, particularly for attacks that depend on pathways independent of CGRP, providing hope for many who suffer from migraines.
Read More
9
CGRP mAb treatment reduces headaches
The effect of calcitonin gene-related peptide monoclonal antibodies on restless legs syndrome in patients with migraine.
Balanced focus on headaches and RLS
We explored how calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) affect headache symptoms in patients who experience both migraines and restless legs syndrome (RLS). This study included 15 female patients averaging 49.1 years old, who received different types of CGRP mAbs—erenumab, galcanezumab, and fremanezumab. Each participant tracked their migraine days in headache diaries, allowing for a detailed analysis of how the treatment impacted their condition over a three-month period.
Our results showed promising findings. After one, two, and three months of treatment, a significant number of participants experienced at least a 50% reduction in their migraine days. Moreover, we noted a marked improvement in headache-related disability and a decrease in central sensitization—a condition where the nervous system becomes more sensitive to pain. Even more encouraging, the severity of restless legs symptoms also improved alongside the headaches.
Overall, our findings suggest that CGRP mAb treatment offers valuable relief for those suffering from migraines, especially for individuals facing the extra challenge of restless legs syndrome. Approximately 87% of patients reported at least minimal improvement in their migraine symptoms, demonstrating the effectiveness of this innovative treatment option.
Our results showed promising findings. After one, two, and three months of treatment, a significant number of participants experienced at least a 50% reduction in their migraine days. Moreover, we noted a marked improvement in headache-related disability and a decrease in central sensitization—a condition where the nervous system becomes more sensitive to pain. Even more encouraging, the severity of restless legs symptoms also improved alongside the headaches.
Overall, our findings suggest that CGRP mAb treatment offers valuable relief for those suffering from migraines, especially for individuals facing the extra challenge of restless legs syndrome. Approximately 87% of patients reported at least minimal improvement in their migraine symptoms, demonstrating the effectiveness of this innovative treatment option.
Read More
Most Useful Reviews
8.8
Dizziness relief
Pumpkin seeds alleviate dizziness and associated symptoms, including headache. They are rich in zinc, copper, and iron, which help to combat type 2 anaemia and improve blood flow to the brain. I consume 50 to 100 grams daily, either roasted without salt or raw. I've even used them to make energy balls and a vegetable burger, which was delicious. My younger siblings have also grown fond of them, and I’m pleased they're enjoying a nutritious snack.
Read More
Medical Researches
SCIENTIFIC SCORE
Likely Very Effective
Based on 2 Researches
9
9
Potential migraine treatment revealed
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.
Highly relevant to migraine treatment
We explored the potential effectiveness of MEDI0618, a monoclonal antibody designed to target protease-activated receptor 2 (PAR2), in alleviating headache pain, particularly migraine. This study used various human and rodent models to evaluate how well MEDI0618 could prevent headache-like symptoms.
Our results showed that MEDI0618 uniquely binds to human PAR2 and effectively prevented pain signals in multiple migraine models. By administering MEDI0618 before triggering migraine-like pain with different methods, we found that it successfully reduced cutaneous allodynia—a condition where even light touch causes pain. This was particularly impressive since MEDI0618 worked even when CGRP receptor activity was blocked by another drug, establishing a broad effectiveness against migraine-related pain.
However, when we looked at a model of post-traumatic headache, MEDI0618 did not show benefits, suggesting it may not be effective for all types of headache pain. Overall, our findings indicate that MEDI0618 could offer a new route for migraine prevention, particularly for attacks that depend on pathways independent of CGRP, providing hope for many who suffer from migraines.
Our results showed that MEDI0618 uniquely binds to human PAR2 and effectively prevented pain signals in multiple migraine models. By administering MEDI0618 before triggering migraine-like pain with different methods, we found that it successfully reduced cutaneous allodynia—a condition where even light touch causes pain. This was particularly impressive since MEDI0618 worked even when CGRP receptor activity was blocked by another drug, establishing a broad effectiveness against migraine-related pain.
However, when we looked at a model of post-traumatic headache, MEDI0618 did not show benefits, suggesting it may not be effective for all types of headache pain. Overall, our findings indicate that MEDI0618 could offer a new route for migraine prevention, particularly for attacks that depend on pathways independent of CGRP, providing hope for many who suffer from migraines.
Read More
9
CGRP mAb treatment reduces headaches
The effect of calcitonin gene-related peptide monoclonal antibodies on restless legs syndrome in patients with migraine.
Balanced focus on headaches and RLS
We explored how calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) affect headache symptoms in patients who experience both migraines and restless legs syndrome (RLS). This study included 15 female patients averaging 49.1 years old, who received different types of CGRP mAbs—erenumab, galcanezumab, and fremanezumab. Each participant tracked their migraine days in headache diaries, allowing for a detailed analysis of how the treatment impacted their condition over a three-month period.
Our results showed promising findings. After one, two, and three months of treatment, a significant number of participants experienced at least a 50% reduction in their migraine days. Moreover, we noted a marked improvement in headache-related disability and a decrease in central sensitization—a condition where the nervous system becomes more sensitive to pain. Even more encouraging, the severity of restless legs symptoms also improved alongside the headaches.
Overall, our findings suggest that CGRP mAb treatment offers valuable relief for those suffering from migraines, especially for individuals facing the extra challenge of restless legs syndrome. Approximately 87% of patients reported at least minimal improvement in their migraine symptoms, demonstrating the effectiveness of this innovative treatment option.
Our results showed promising findings. After one, two, and three months of treatment, a significant number of participants experienced at least a 50% reduction in their migraine days. Moreover, we noted a marked improvement in headache-related disability and a decrease in central sensitization—a condition where the nervous system becomes more sensitive to pain. Even more encouraging, the severity of restless legs symptoms also improved alongside the headaches.
Overall, our findings suggest that CGRP mAb treatment offers valuable relief for those suffering from migraines, especially for individuals facing the extra challenge of restless legs syndrome. Approximately 87% of patients reported at least minimal improvement in their migraine symptoms, demonstrating the effectiveness of this innovative treatment option.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
8.8
Dizziness relief
Pumpkin seeds alleviate dizziness and associated symptoms, including headache. They are rich in zinc, copper, and iron, which help to combat type 2 anaemia and improve blood flow to the brain. I consume 50 to 100 grams daily, either roasted without salt or raw. I've even used them to make energy balls and a vegetable burger, which was delicious. My younger siblings have also grown fond of them, and I’m pleased they're enjoying a nutritious snack.
Read More
